Research programme: protein therapeutics - Acceleron

Drug Profile

Research programme: protein therapeutics - Acceleron

Alternative Names: ACE 1334; ACE-1332; ACE-2395; ACE-2536; ACE-2798

Latest Information Update: 23 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acceleron Pharma
  • Class Antifibrotics; Antineoplastics; Proteins
  • Mechanism of Action TGF-beta superfamily protein-modulators; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Fibrosis; Lung disorders; Myelofibrosis

Most Recent Events

  • 19 Sep 2017 Preclinical trials in Lung disorders in USA (unspecified route)
  • 17 Mar 2016 Preclinical trials in Cancer in USA (unspecified route)
  • 17 Mar 2016 Preclinical trials in Fibrosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top